ArticleTranslational lung cancer research2022

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration.

Xiaobo Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.